Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-07-14
1997-04-22
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514835, 514885, 514900, 514901, 514902, 5361231, 53612312, A61K 31715, C07H 100
Patent
active
056229402
ABSTRACT:
Methods of treating or preventing infection-induced oral tissue destruction or gingivitis in a mammal, comprising administering a therapeutically effective amount of a .beta.(1,3)-glucan, such as poly-.beta.(1-6)-glucotriosyl-.beta.(1-3)-glucopyranose glucan (PGG-glucan), are disclosed.
REFERENCES:
patent: 3931398 (1976-01-01), Gaffar et al.
patent: 3943247 (1976-03-01), Komatsu et al.
patent: 4138479 (1979-02-01), Truscheit et al.
patent: 4237266 (1980-12-01), Sugiura et al.
patent: 4430322 (1984-02-01), Stoudt et al.
patent: 4471402 (1984-09-01), Williams et al.
patent: 4707471 (1987-11-01), Larm et al.
patent: 4739046 (1988-04-01), Di Luzio
patent: 4810646 (1989-03-01), Jamas et al.
patent: 4833131 (1989-05-01), Williams et al.
patent: 4900722 (1990-02-01), Williams et al.
patent: 4973472 (1990-11-01), Morisaki
patent: 5032401 (1991-07-01), Jamas et al.
patent: 5328829 (1994-07-01), Stashenko
Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ed. Gilman et al., 8th Edition, p. 1029, (1990).
Stashenko, P., et al., "Inhibition of Periapical Bone Resorption by a Biological Response Modifier", J. Dent. Res. 73 (IADR Abstracts) 1994; Abstract 146.
Manners, D.J., et al., "The Structure of a .beta.-(1.fwdarw.3)-D-Glucan from Yeast Cell Walls," Biochem. J., 135:19-30 (1973).
Onderdonk, A.B., et al., "Anti-Infective Effect of Poly-.beta.1-6-Glucotriosyl-.beta.1-3-Glucopyranose Glucan In Vivo," Infec. Immun., 60(4):1642-1647 (1992).
Williams, D.L., et al., "Pre-clinical Safety Evaluation of Soluble Glucan," Int. J. Immunopharmac., 10(4):405-414 (1988).
Janusz, M.J., et al., "Isolation of Soluble Yeast .beta.-Glucan that Inhibit Human Monocyte Phagocytosis Mediated by .beta.-Glucans Receptors," J. Immunol., 137:3270-3276 (1986).
Miyazaki, T., et al., "Structural Examination of Antitumour, Water-Soluble Glucans from Grifora umbellata by Use of Four Types of Glucanese," Carbohydrate Research, 65:235-243 (1978).
Reiskind, J.B. and Mullins, J.T., "Molecular Architecture of the Hyphal Wall of Achlya ambisexualis Raper. II. Ultrastructural Analyses and a Proposed Model," J. Microbiol., 27:1100-1105 (1981).
Sherwood, E.R., et al., "Soluble Glucan and Lymphokine-activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases," Chemical Abstracts, 108:179752V (1988).
Williams, D.L., et al., "Pre-clinical Safety Evaluation of Soluble Glucan," Chemical Abstracts, 109:66566q (1988).
Williams, D.L., et al., "Development of a Water-Soluble, Sulfated (1.fwdarw.3)-.beta.-D-Glucan Biological Response Modifier Derived from Saccharomyces cerevisiae," Carbohydrate Research, 235:247-257 (1992).
Hara, C., et al., "A Branched (1.fwdarw.3)-.beta.-D-Glucan From a Water Extract of Dictyophora indusiata FISCH," Carb. Res., 145:237-246 (1986).
Fleet, G.H., et al., "Isolation and Composition of an Alkali-soluble Glucan from the Cell Walls of Saccharomyces cerevisiae," Journal of General Microbiology, 94:180-192 (1976).
Sherwood, E.R., et al., "Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan," Int. J. Immunopharmac., (3):261-267 (1987).
Fleet, G.H., et al., "Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls of Saccharomyces cerevisiae," Chemical Abstracts, 85:89819z (1976).
Bacon, J., et al., "The Glucan Components of the Cell Wall of Baker's Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultreastructure," Biochem. J., 114:557-567 (1969).
Goldman, R., "Induction of a .beta.-1, 3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid of 1,25-dihydroxyvitamin D.sub.3," Immunology, 63:319-324 (1988).
Bacon, J.S.D., et al., "Glucan Components of the Cell Wall of Bakers' Yeast (Saccharomyces cerevisiae) Considered in Relation to its Ultrastructure," Chemical Abstracts, 71:109168c (1969).
Konopski, Z., et al., "Phagocytosis of .beta.-1,3-D-Glucan-Derivatized Microbeads by Mouse Peritoneal Macrophages Involves Three Different Receptors," Scand. J. Immunol., 33:297-306 (1991).
Pretus, H.A., et al., "Isolation, Physicochemical Characterization and Preclinical Efficacy Evaluation of Soluble Scleroglucan," The Journal of Pharmacology and Experimental Therapeutics, 500-510 (1991).
Williams, D.L., et al., "Development, Physicochemical Characterization and Preclinical Efficacy Evaluation of Water Soluble Glucan Sulfate Derived from Saccharomyces cerrevisiae," Immunopharmacology, 22:139-156 (1991).
Williams, D.L., et al., "A Sequential Multi-Assay Protocol for the Preclinical Assessment of Natural Product Complex Carbohydrate Immunomodulators," Develop. Biol. Standards., 77:129-136 (1992).
Browder, W., et al., "Beneficial Effect of Enhanced Macrophage Function in the Trauma Patient," Ann. Surg., 605-613 (1990).
Chihara, G., et al., "Lentinan as a Host Defense Potentiator (HPD)," Int. J. Immunotherapy, V(4):145-154 (1989).
Stashenko, P., et al., "Inhibition of Periapical Bone Resorption by a Biological Response Modifier PGG Glucan", J. Dent. Res. 74(1):323-330 (1995).
Alpha-Beta Technology
Kight John
Lee Howard C.
LandOfFree
Inhibition of infection-stimulated oral tissue destruction by .b does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of infection-stimulated oral tissue destruction by .b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of infection-stimulated oral tissue destruction by .b will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-341622